Previous Article | Next Article ![]()
Clinical and Vaccine Immunology, August 2006, p. 969-971, Vol. 13, No. 8
1071-412X/06/$08.00+0 doi:10.1128/CVI.00149-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
Division of Clinical Microbiology, Department of Laboratory Medicine, All India Institute of Medical Sciences, New Delhi 110029, India
Received 21 April 2006/ Returned for modification 22 May 2006/ Accepted 30 May 2006
In the present study, anti-Leishmania immunoglobulin G (IgG) avidity was used to estimate the approximate time of disease manifestation. Significant differences (P < 0.0001) were found between the levels of anti-rKE-16 IgG avidity in leishmaniasis patients with recent and chronic diseases. More than 76% of patients with an illness duration of less than 6 months had avidity of less than 70%, 94% of patients had less than 80% avidity, and all (100%) patients with illness of more than 6 months had avidity values higher than 70%. The study showed that avidity could successfully be used to pinpoint the duration of leishmaniasis.
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»